Wolff Wiese Magana LLC Has $56,000 Holdings in Johnson & Johnson $JNJ

Key Points

• Wolff Wiese Magana LLC drastically reduced its holdings in Johnson & Johnson by 92.3%, owning only 366 shares valued at $56,000 after selling 4,390 shares in the second quarter.
• Institutional investors own approximately 69.55% of Johnson & Johnson's stock, with notable increases in positions from firms such as Nuveen LLC and Assenagon Asset Management.
• Johnson & Johnson recently declared a quarterly dividend of $1.30 per share, representing an annualized dividend of $5.20 and a yield of 2.8%.

Wolff Wiese Magana LLC cut its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 92.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 366 shares of the company's stock after selling 4,390 shares during the quarter. Wolff Wiese Magana LLC's holdings in Johnson & Johnson were worth $56,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Nuveen LLC bought a new position in shares of Johnson & Johnson during the first quarter valued at about $1,369,188,000. Bank of New York Mellon Corp raised its position in Johnson & Johnson by 26.4% in the first quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company's stock worth $3,844,580,000 after acquiring an additional 4,842,582 shares during the period. Pacer Advisors Inc. increased its stake in shares of Johnson & Johnson by 1,382.0% in the first quarter. Pacer Advisors Inc. now owns 3,030,084 shares of the company's stock worth $502,509,000 after purchasing an additional 2,825,626 shares in the last quarter. Assenagon Asset Management S.A. increased its stake in shares of Johnson & Johnson by 159.6% in the second quarter. Assenagon Asset Management S.A. now owns 4,159,260 shares of the company's stock worth $635,327,000 after purchasing an additional 2,557,388 shares in the last quarter. Finally, Kingstone Capital Partners Texas LLC purchased a new position in shares of Johnson & Johnson in the second quarter worth about $401,420,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the business's stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares of the company's stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $185.40 on Wednesday. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The firm has a market capitalization of $446.51 billion, a PE ratio of 19.83, a P/E/G ratio of 2.31 and a beta of 0.40. The company has a 50 day moving average price of $175.11 and a 200-day moving average price of $162.34. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $185.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. During the same quarter last year, the firm posted $2.82 earnings per share. The firm's revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, equities research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were issued a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.8%. Johnson & Johnson's payout ratio is currently 55.61%.

Analysts Set New Price Targets

A number of analysts recently weighed in on JNJ shares. The Goldman Sachs Group upped their target price on shares of Johnson & Johnson from $185.00 to $186.00 and gave the stock a "buy" rating in a report on Friday, September 19th. Wall Street Zen raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Saturday, September 13th. Royal Bank Of Canada increased their price target on shares of Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a research report on Thursday, July 17th. Guggenheim raised shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and increased their price target for the company from $167.00 to $206.00 in a research report on Tuesday, September 23rd. Finally, JPMorgan Chase & Co. raised their target price on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a "neutral" rating in a research report on Tuesday, September 16th. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, Johnson & Johnson currently has an average rating of "Moderate Buy" and a consensus price target of $181.40.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.